Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, with a peak incidence at birth. About 40% of children are diagnosed in the first year of life, and by 6 years of age, more than 90% of children will have presented with the disease. Unlike cancers in adults, where many common malignancies can be preclinically detected, including the 4 most prevalent cancers—lung, colon, prostate, and breast—no pediatric cancer was deemed easily detectable by screening. The 1 exception was NB because it has been known for decades that 90% of patients presenting clinically excrete elevated catecholamine metabolites in their urine. Furthermore, if children present with NB at a young age—specifically, under 18 months of age—the prognosis is outstanding, with about 90% of cases cured. Based on these facts, Sawada and Japanese colleagues pioneered NB screening programs in the 1970s ( 1), with early results suggesting that overall survival in the children screened improved. Unfortunately, survival can look artificially increased if screening programs diagnose patients whose tumors would have spontaneously regressed, a known phenomenon in NB. One must determine population-based mortality to determine true efficacy of any such intervention.

This publication has 11 references indexed in Scilit: